Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Southampton spin-out scoops major healthcare prize for revolutionary liver disease treatments

14.11.2005


Southampton-based company iQur has scooped the 2005 Medical Futures Department of Health Award for Best National Healthcare Innovation for its Hepatitis C diagnostic service, that can revolutionise the cost-effectiveness of treatment for Hepatitis C. iQur, formerly named HepCgen Limited, spun out from the University of Southampton in 2003.



The Medical Futures Innovations Awards are often referred to as the ‘Oscars of Healthcare’. iQur was presented with the Award for its research into the detection, treatment and monitoring of Hepatitis C and other liver diseases at the awards ceremony in London.

Accepting the Award from supermodel Caprice, Professor William Rosenberg, iQur’s founding Chief Scientific Officer and Professor of Hepatology at the University of Southampton, said: ‘This award is testament to the importance and success of our diagnostic services. iQur is the first Southampton-based company to be recognised at this level and we achieved this as a result of our expert team and their tremendous dedication to develop better care for the increasing threat of Hepatitis C across the globe. iQur’s strategies enable therapies to be tailored to the individual patient – potentially reducing treatment time and side effects, saving the NHS millions of pounds in clinical and pharmaceutical expenses. Following this innovation will be our simple blood test to reduce the requirement of serial liver biopsy across Europe, then the introduction of better treatment for Hepatitis C’


Speaking on behalf of the University of Southampton, Dr Tony Raven, Director of its Centre for Enterprise and Innovation (CEI) said, ‘Winning this very prestigious and hotly contested award is a fitting tribute to the work of Professor Rosenberg and his scientific team at iQur Limited.’ Earlier this year two other University of Southampton spin-out companies, SPI Lasers and OHM, were finalists in the Royal Academy of Engineering’s prestigious MacRobert Award, which recognises the successful development of innovative ideas in engineering. ‘The recognition our spin-out companies are receiving from these awards reflects the real commercial significance of our research and technology,’ he added.

As well as recognition within the medical community, iQur has also attracted positive attention from the investment community, and has successfully raised further investment of £2.6 million in an oversubscribed funding round. The funding will be used to establish the company’s Diagnostic Services business, the iQur® Speciality Pharmaceutical distribution division and grow various therapeutic in-licensing agreements.

Commenting on the investment and Award, David Norwood, Board Director and CEO of IP2IPO, a major investor in iQur, said: ‘UK universities are originators of some of the best novel intellectual property in the world, and the University of Southampton and the progress of the iQur team to deliver innovation to the global problem of liver disease, specifically, Hepatitis C, is an inspiration to all our portfolio companies, and fully reflective of our mission. iQur’s progress is underlined by the success of this financing round.’

In addition, iQur has also extended its focus and pipeline beyond Hepatitis C into liver fibrosis and secured a licensing deal with The University of Southampton. Liver fibrosis is the result of fatty liver disease, obesity, hepatitis, alcoholic liver disease and others. Over the last 20 years, the University has achieved an international reputation for its study of the pathology of fibrosis, cirrhosis, then cancer of the liver.

Commenting on these significant announcements, Paul Colford, CEO, said: ‘I am delighted that iQur’s ground breaking research into the diagnosis, treatment and monitoring of major liver diseases has been recognised on such a wide range of fronts, by the Department of Health, the investment community and the University, and underlines our company’s goal to become THE liver disease company.’

Sarah Watts | alfa
Further information:
http://www.soton.ac.uk

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Osaka university researchers make the slipperiest surfaces adhesive

18.10.2017 | Materials Sciences

Space radiation won't stop NASA's human exploration

18.10.2017 | Physics and Astronomy

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>